
<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=undefined&type=result"></script>');
-->
</script>pmid: 35491621
Abstract According to CHOICE-01, a phase III trial in China, the PD-1 inhibitor toripalimab plus chemotherapy improves progression-free survival in patients with untreated non–small cell lung cancer lacking actionable mutations. The findings boost combination chemo–immunotherapy, rather than chemotherapy alone, as the new standard for this population.
Lung Neoplasms, Clinical Trials, Phase III as Topic, Carcinoma, Non-Small-Cell Lung, Humans, Immunotherapy, Antibodies, Monoclonal, Humanized
Lung Neoplasms, Clinical Trials, Phase III as Topic, Carcinoma, Non-Small-Cell Lung, Humans, Immunotherapy, Antibodies, Monoclonal, Humanized
| citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 3 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 10% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
